Convera Appoints Industry Leader Meaghan Riley as Chief Commercial Officer to Scale Commercial Growth and Expand Revenue Opportunities
29.1.2026 17:14:00 CET | Business Wire | Press Release
Convera, a global leader in commercial payments, today announces the appointment of Meaghan Riley to Chief Commercial Officer, as the company continues its growth trajectory, expands to new markets, and drives scalable revenue opportunities across geographies and sectors. Prior to Convera, Meaghan was Chief Operating Officer for Google Cloud North America, where she led a major go-to-market transformation and launched high-growth segments.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260129799440/en/
Meaghan Riley, Chief Commercial Officer, Convera
“Meaghan’s impressive career journey and proven track record brings exceptional experience and unique assets that will strengthen our leadership team at this pivotal moment in Convera’s journey,” said Patrick Gauthier, CEO, Convera. “Meaghan’s leadership will be instrumental in delivering on our commitment to make global business payments simpler and smarter—serving our customers with excellence while building a high performing, aligned organization.”
“As Convera continues to lead the market and deliver next generation commercial payments globally, Meaghan will play a key role in advancing our vision. She brings to Convera the know-how to enhance our market presence and unify our go-to-market (GTM) teams into a powerful, revenue growth engine,” stated Bill McNichols, Convera Chairman of the Board, co-founder and managing partner of Goldfinch partners.
Prior to leading operations for Google Cloud, Meaghan held senior leadership roles at DocuSign and SAP. She has delivered exceptional growth and financial results across industries, having led complex operations in North America, Europe, Asia, and Latin America. Her financial acumen and strong capabilities leading GTM teams will help Convera position itself as a global leader in business payments. She is a passionate advocate for diversity and inclusion, championing programs to foster equity and representation in the workplace.
“I am proud and energized to join this ambitious leadership team as they continue to lead the market,” said Meaghan Riley, newly appointed Chief Commercial Officer, Convera. “Convera’s core values and growth mindset attracted me to join the movement they are leading, and together, I am excited to unlock new revenue opportunities and meet the rapidly growing global customer demand for modern commercial payments.”
Convera Drives Sustainable Growth Across Segments
“We knew 2025 would be an ambitious year for Convera. Like many organizations, we’ve had to navigate through uncertainty, but we’ve responded with resilience in a moment of challenge and complexity. As a result, we’ve made meaningful, measurable accomplishments worthy of celebrating,” said Gauthier.
In 2025, Convera accelerated its transformation. The company delivered record performance, achieving double digit revenue growth and increased total turnover to nearly USD 190B with payments transaction capacity reaching more than 18,000 transactions per hour. The company was recognized for its services by marquis customers across segments, including Identity Digital, IDB Global Federal Credit Union, Betcris, Melecs and Prisma Capital, to name a few.
Convera also invested in future-proofing security and compliance measures by completing its SOC2 certification, in addition to establishing a new strategic collaboration with iPID, a global Know Your Payee (KYP) verification provider, to enhance our payment validation process and comply with the Verification of Payee (VoP) mandate issued by the European Union. Furthermore, Convera successfully deployed AI-powered solutions across the entire organization, to elevate productivity and enable teams in engineering, sales, marketing, and operations to reach new heights of innovation and impact.
About Convera
Convera is a global leader in commercial payments. With an unrivaled regulatory footprint and a financial network spanning more than 140 currencies and 200 countries and territories, Convera is reimaging the future of business payments. We combine tech-led payment solutions with deep expertise in foreign exchange, risk management, and compliance. From small businesses to CFOs and treasurers, we’re helping our customers grow with confidence. Convera makes business payments simple, smart, and secure.
To learn more about Convera, visit https://convera.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260129799440/en/
Contacts
pr@convera.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press Release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press Release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press Release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press Release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press Release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom